Pembrolizumab Could Delay Radical Cystectomy in BCG-unrespon

Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy.

Related Keywords

Columbus , Ohio , United States , Ohio State University , Chicago , Illinois , American , Astellas Medivation , Ohio State University Comprehensive Cancer Center , Johnson , Ohio State University Wexner Medical Center , American Urological Association , Division Of Urologic Oncology , Bacillus Calmette Gu , Urological Association , Annual Meeting , Urologic Oncology , Merck Sharp , Bacillus Calmette Guerin , Keynote 057 Trial , Nct02625961 , Bacillus Calmette Guérin , Bcg , Non Muscle Invasive Bladder Cancer , Erica Singer , D , American Urological Association Annual Meeting , Aua Annual Meeting , Pembrolizumab ,